ROS1 and non-small cell lung carcinoma: Entrectinib has been approved for the treatment of adult and pediatric (> 12 years) patients with tumors that harbor neurotrophic TRK (NTRK) 1/2/3 gene fusions and adults with ROS1-positive non-small cell lung cancer (NSCLC) [4–6].